Eli Lilly & Co says its once-weekly injectible drug, dulaglutide, has outperformed three other widely taken drugs in three just-concluded Phase III studies. According to Lilly, dulaglutide, a GLP-1 analog, worked better to reduce HbA1c levels than metformin, Merck & Co.’s Januvia (sitagliptin), read more »

Recently approved T2 treatment Bydureon is becoming available in pharmacies in the USA nationwide this month. The approval was in part based on clinical experience with Byetta (exenatide) injection, a twice-daily form of exenatide that has been available in the U.S. since read more »

Survey finds increased need for more medicines like Byetta and Januvia Initially reported in July 2009, a survey, “A Clinician and Payer Perspective on Changing Dynamics in the Diabetes Market: Is There Room for New GLP-1 Analogues or DPP-IV Inhibitors?,” published by Waltham, read more »